Alamar Biosciences, Inc. (ALMR) Key Metrics
ALMR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.75B
- Enterprise value
- $2.04B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 17.5
- Price / book
- 7.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
ALMR key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsALMR returns How much profit the business earns on the capital it uses.
Return on assets+10.9 pts
−20.6%
2025 · hover or tap a bar for each year
20242025
Free cash flow margin+152.2 pts
−80.8%
2025 · hover or tap a bar for each year
20242025
Asset turnover+204.9%
0.51
2025 · hover or tap a bar for each year
20242025
ALMR per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+195.2%
$1.12
2025 · hover or tap a bar for each year
20242025
Earnings per share
−$0.45
2025 · hover or tap a bar for each year
20242025
Free cash flow per share
−$0.90
2025 · hover or tap a bar for each year
20242025
Book value per share
−$2.39
2025 · hover or tap a bar for each year
20242025
Shares outstanding0.0%
66.5M
2025 · hover or tap a bar for each year
20242025
ALMR financial health Debt, liquidity and how easily interest is covered.
Net debt+$57.7M
$11.5M
2025 · hover or tap a bar for each year
20242025
Current ratio−37.9%
3.99
2025 · hover or tap a bar for each year
20242025
Interest coverage
-78.1
2025 · hover or tap a bar for each year
20242025
Debt / assets+33.8%
0.30
2025 · hover or tap a bar for each year
20242025
ALMR efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−57 days
49 days
2025 · hover or tap a bar for each year
20242025
Days of inventory−21 days
297 days
2025 · hover or tap a bar for each year
20242025
Days payables outstanding−69 days
68 days
2025 · hover or tap a bar for each year
20242025
Cash conversion cycle−9 days
279 days
2025 · hover or tap a bar for each year
20242025
Capex / revenue−4.9 pts
8.6%
2025 · hover or tap a bar for each year
20242025
ALMR returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ALMR debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ALMR key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $1.12 | $0.38 |
| Earnings per share | −$0.45 | −$0.71 |
| Operating cash flow per share | −$0.81 | −$0.83 |
| Free cash flow per share | −$0.90 | −$0.88 |
| Cash per share | $0.45 | $1.19 |
| Book value per share | −$2.39 | −$2.01 |
| Tangible book value per share | −$2.42 | −$2.04 |
| Capex per share | $0.10 | $0.05 |
| Debt per share | $0.62 | $0.50 |
| Shares outstanding | 66.5M | 66.5M |
| Change in shares outstanding | −0.0% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −20.6% | −31.5% |
| Return on tangible assets | −21.6% | −31.9% |
| Free cash flow margin | −80.8% | −233.1% |
| Financial health | ||
| Total debt | $41.5M | $33.1M |
| Cash & short-term investments | $30.0M | $79.4M |
| Net debt | $11.5M | −$46.3M |
| Debt / assets | 0.30 | 0.22 |
| Current ratio | 3.99 | 6.43 |
| Quick ratio | 2.37 | 5.56 |
| Interest coverage | -78.1 | -23.9 |
| Working capital | $71.0M | $90.1M |
| Invested capital | −$147.5M | −$179.7M |
| Tangible asset value | −$160.9M | −$135.5M |
| Net current asset value | −$204.2M | −$176.2M |
| Graham net-net per share | −$3.61 | −$2.87 |
| Capital allocation | ||
| Capex / revenue | 8.6% | 13.5% |
| Capex / depreciation | 1.65 | 1.06 |
| Stock-based compensation / revenue | 3.9% | 3.5% |
| R&D / revenue | 50.5% | 156.0% |
| SG&A / revenue | 47.9% | 75.3% |
| Efficiency | ||
| Days sales outstanding | 49.4 | 106.3 |
| Days of inventory on hand | 296.9 | 318.0 |
| Days payables outstanding | 67.7 | 136.6 |
| Cash conversion cycle (days) | 278.6 | 287.8 |
| Receivables turnover | 7.39 | 3.43 |
| Payables turnover | 5.39 | 2.67 |
| Inventory turnover | 1.23 | 1.15 |
| Asset turnover | 0.51 | 0.17 |
| Average receivables | $10.0M | $7.3M |
| Average payables | $6.0M | $6.2M |
| Average inventory | $26.4M | $14.4M |
| Intangibles / total assets | 1.4% | 1.4% |
Computed from ALMR's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ALMR valuation and financial ratios
It ended the year with $41.5 million of debt and $30.0 million in cash and short-term investments, net debt of $11.5 million.
See the ALMR income statement, the ALMR chart for price history, or the ALMR stock overview for the latest quote and news.
ALMR key metrics FAQ
How much debt does Alamar Biosciences have?
Alamar Biosciences had total debt of $41.5 million at the end of fiscal 2025.
What is Alamar Biosciences's current ratio?
Alamar Biosciences's current ratio was 3.99 at the end of fiscal 2025: current assets were 3.99 times current liabilities.